DURECT Corporation announced that its Posimir (SABER – Bupivacaine) for post-surgical pain failed a Phase III clinical trial.
Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.
Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Swiss-based AstraZeneca. The deal appears consistent with Ramaswamy’s business model – acquire cast-off compounds from big pharmaceutical companies at bargain-bin prices and convince investors to invest in developing them.
Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.
Ignyta updated results from its STARTRK-2 clinical trial of entrectinib in non-small cell lung cancer (NSCLC), causing company stock to jump about five percent before settling down.
Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
Eli Lilly signed an R&D collaboration deal with CureVac that could total up to $1.8 billion to develop and commercialize up to five possible cancer vaccines.
Johnson & Johnson indicated in its third-quarter 2017 financial announcement that the company is dropping two of its pipeline drugs.
Switzerland-based Novartis is closing the company’s generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
Takeda Pharmaceutical is jumping into the $40 billion market for nonalcoholic steatohepatitis (NASH) and other diseases of the liver with a $470+ million investment into Virginia-based HemoShear Therapeutics LLC.
Mid-stage data shows that Pfizer’s lorlatinib could provide benefits to lung cancer patients who exhibit related brain tumors.
Exelixis’s Cabometyx (cabozantinib) hit key endpoints of overall survival in its Phase III liver cancer trial.
Incyte Claims Flexus Lured Away CSO and Its IDO Secrets, Then Sold Itself to Bristol-Myers in $1.25B Deal
Incyte leveled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former chief scientific officer who had access to Incyte’s scientific research.
Through a strategic collaboration deal with Roche, Warp Drive Bio will use its Genome Mining Platform to investigate potential antibiotics for drug-resistant Gram-negative bacteria.
The U.S. FDA identified unnamed deficiencies in Antares Pharma’s NDA for Xyosted that halted discussion of labeling and postmarketing requirements.
An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage Inc. To maintain operations, the company is terminating 17 employees, about 71 percent of its workforce.
Shares of AcelRx Pharmaceuticals plunged more than 60 percent after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.
Basel, Switzerland-based Novartis has decided not to sell its $14 billion stake in Swiss rival Roche.
Two months after slashing 28 percent of its workforce as part of a strategic review, Ardelyx Inc. announced positive Phase III results for tenapanor, its irritable bowel syndrome with constipation (IBS-C).
Trevena Inc. is banking its future on possible approval of troubled pain medication Olinvo eight months after Phase III data raised some questions over the drug’s safety profile.